L-type calcium channels as drug targets in CNS disorders

Area of Science:

• Neuroscience
• Pharmacology
• Cardiovascular Medicine

Background:

• L-type calcium channels are vital for electrically excitable cells, including neurons, impacting brain, muscle, endocrine, and sensory functions.
• Altered L-type calcium channel activity is increasingly linked to neurological conditions like Parkinson disease, febrile seizures, and neuropsychiatric disorders.
• Existing organic calcium channel blockers, primarily targeting Cav1.2 in the cardiovascular system, have a proven safety record.

Purpose of the Study:

• To review the evidence implicating L-type calcium channel isoforms (Cav1.2 and Cav1.3) in human brain pathologies.
• To explore the therapeutic potential of existing calcium channel blockers for neurological disorders.
• To discuss the rationale and ongoing development of Cav1.3-selective compounds.

Main Methods:

• Literature review of studies on L-type calcium channel function in the brain.
• Analysis of clinical data on the use of calcium channel blockers in neurological conditions.
• Examination of research on the development of selective Cav1.3 inhibitors.

Main Results:

• Evidence suggests a role for both Cav1.2 and Cav1.3 in brain diseases.
• Current calcium channel blockers inhibit both brain isoforms, offering potential therapeutic avenues.
• Development of Cav1.3-selective blockers is a focus for targeted neurological therapies.

Conclusions:

• Pharmacological inhibition of brain L-type calcium channels holds therapeutic promise for neurological diseases.
• Existing blockers may offer benefits, but selectivity for brain isoforms like Cav1.3 is desirable.
• Further research into Cav1.3-selective compounds could lead to novel treatments for brain disorders.